CVE-2017-10048
Vulnerability in the Oracle Enterprise Repository component of Oracle Fusion Middleware (subcomponent: Web Interface).
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (1.89%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
Vulnerability in the Oracle Enterprise Repository component of Oracle Fusion Middleware (subcomponent: Web Interface). Supported versions that are affected are 11.1.1.7.0 and 12.1.3.0.0. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Enterprise Repository. Successful attacks require human interaction from a person other than the attacker and while the vulnerability is in Oracle Enterprise Repository, attacks may significantly impact additional products. Successful attacks of this vulnerability can result in unauthorized access to critical data or complete access to all Oracle Enterprise Repository accessible data as well as unauthorized update, insert or delete access to some of Oracle Enterprise Repository accessible data. CVSS 3.0 Base Score 8.2 (Confidentiality and Integrity impacts). CVSS Vector: (CVSS:3.0/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:L/A:N).
- CVSS 3.0
- 8.2 HIGHCVSS:3.0/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:L/A:N
- EPSS
- 1.89% probability · 78th percentile
- CISA KEV
- Not listed
- Affected
- oracle/enterprise repository
- Source
- secalert_us@oracle.com
References
- http://www.oracle.com/technetwork/security-advisory/cpujul2017-3236622.htmlPatch, Vendor Advisory
- http://www.securityfocus.com/bid/99771Third Party Advisory, VDB Entry
- http://www.securitytracker.com/id/1038940Third Party Advisory, VDB Entry
- http://www.oracle.com/technetwork/security-advisory/cpujul2017-3236622.htmlPatch, Vendor Advisory
- http://www.securityfocus.com/bid/99771Third Party Advisory, VDB Entry
- http://www.securitytracker.com/id/1038940Third Party Advisory, VDB Entry
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.